Egyptian Firm Develops Vaccine as Ebola Outbreak Escalates in DRC

An Egyptian pharmaceutical company called Minapharm is developing a vaccine to combat the Bundibugyo strain of the ebola virus currently affecting the Democratic Republic of Congo. The company will receive up to 16.5 million US dollars from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the candidate through laboratory stages to phase 1 clinical trials. This vaccine, developed by Minapharm subsidiary ProBioGen, is one of five candidates funded by CEPI. Other developers include Moderna, the University of Oxford, the Serum Institute of India, Hilleman, and Public Health Vaccines. The World Health Organization (WHO) has also recommended large scale human trials of Ervebo, a vaccine already approved for the Zaire strain, to see if it provides cross protection against the Bundibugyo strain.

The outbreak is described as the second largest ebola epidemic ever recorded. Reports indicate over 5,600 confirmed cases and more than 2,700 deaths since the outbreak began on May 15. The virus is spreading rapidly across 56 health zones. The WHO has declared the situation a public health emergency of international concern, while Africa CDC has labeled it a continental security emergency.

Perspectives on the crisis vary by framing. A center lean source emphasizes the scientific progress and the importance of African capacity to manufacture its own medical tools. A center left lean source frames the crisis as a failure of response capacity, highlighting how decades of armed conflict and insecurity have weakened social services and eroded trust. A center right lean source focuses on the logistical risks, specifically the fear that the Congo river network is becoming a conduit for the virus.